COVID-19 is impacting all of us and challenging previous ways of working. This is a period of disruption.  

However, we can embrace this new reality with confidence and adapt the way we work, the way we strategize, and the way we generate, use, and disseminate 
real world evidence (RWE) to better inform decision making. 

Stakeholders across the healthcare ecosystem (regulators, payers, providers, and patients) are adopting new solutions enabled by technology to navigate 
this era of change. 

In this new reality, RWE will take a more prominent role to improve patient outcomes, meet stakeholder needs, and answer business questions.  

Join Pharmaceutical Executive®, IQVIA, and leading healthcare industry thought leaders to better understand the role and importance of RWE during and after COVID-19, what it means for your business today, and how you can plan for tomorrow with confidence.

Your computer

On-Demand

Free virtual event

Sessions and Panel Discussions

Hear from RWE speakers across the industry, learn about evidence generation and dissemination in our new reality, and discover how you can continue accelerating your business forward.

Keynote

Murray Aitken
Executive Director
IQVIA Institute of Human Data Science  

Markus Gores, PhD
Vice President of Thought Leadership EMEA
IQVIA

Booth and Demos

Talk with us live via chat, ask questions, get answers, and experience live product demos.

Featured Speakers

Featured Topics

Your computer
Free virtual event

On-Demand

COVID-19 is impacting all of us and challenging previous ways of working. This is a period of disruption.  

However, we can embrace this new reality with confidence and adapt the way we work, the way we strategize, and the way we generate, use, and disseminate real world evidence (RWE) to better inform decision making. 

Stakeholders across the healthcare ecosystem (regulators, payers, providers, and patients) are adopting new solutions enabled by technology to navigate this era of change.

In this new reality, RWE will take a more prominent role to improve patient outcomes, meet stakeholder needs, and answer business questions 

Join Pharmaceutical Executive®, IQVIA, and leading healthcare industry thought-leaders to better understand the role and importance of RWE during and after COVID-19, what it means for your business today, and how you can plan for tomorrow with confidence.

Sessions and Panel Discussion

Hear from RWE speakers across the industry, learn about evidence generation and dissemination in our new reality, and discover how you can continue accelerating your business forward

Keynote

Murray Aitken 
Executive Director
IQVIA Institute of Human Data Science 

Markus Gores, PhD
Vice President of Thought Leadership EMEA
IQVIA

Booth and Demos

Talk with us live via online chat, ask questions, get answers, and experience live product demos

Lisa Taylor
Vice President
Head of Europe Consulting
EMEA Commercial and Consulting Services
IQVIA

Stella Karantzoulis, PhD
ABPP-CN
Senior Scientific Advisor
IQVIA

Anke van Engen
Senior Principal
Integrated Value Assessment
IQVIA

Mary New, MBA, DPhil
Senior Principal
Patient Centered Endpoints
IQVIA

Ian Bonzani
Senior Principal
Real World Networks Team
IQVIA

Nancy Dreyer, PhD, MPH, FISPE, Fellow DIA
Chief Scientific Officer
IQVIA

Future trends and 
lasting impacts

What new approaches, technologies, and 
behaviors are here to stay and what is their impact on the healthcare ecosystem? 

For example, how will digital technologies like telehealth impact healthcare delivery?

RWD and RCTs: Filling 
evidence gaps

How will the pressure on 
site-based research and the need to reduce study-induced burden on sites shift the balance between randomized clinical trials (RCTs) and RWE for regulatory submissions? How can RWD improve clinical trial efficiencies, fill evidence gaps, and accelerate approvals?

Accelerated RWE acceptance for decision making

Which current dynamics will further accelerate the 
acceptance of RWE by 
regulators and how will payers change their decision making criteria as they operate in a 
more cost-constrained environment?

Patient impacts and research participation

How are patients being affected by COVID-19, both in research and practice? What will be the 
long-term impact on patients willingness to participate in research and share their health data?

Role of RWE across the product lifecycle

What will be the implications to pharma and the role of RWE across the product life cycle? 

Will RWE generation and dissemination take a more prominent place in demonstrating value post-launch as part of commercialization efforts?

Moke Sharma 
Head of Development Operations & Quantitative Sciences
Alexion Pharmaceuticals

Konstantina Skaltsa, PhD
Associate Director Statistics
Patient Centered Endpoints
IQVIA

Markus Gores, PhD
Vice President 
Thought Leadership EMEA
IQVIA

Murray Aitken
Executive Director 
IQVIA Institute of Human Data Science 

Andrea Spannheimer
Senior VP 
Global Head of Real World Offerings
Innovations and Partnerships
IQVIA

Jean-François Bergmann, M.D
Professor of Internal Medicine 
Pharmacology and Therapeutics
University of Paris

Christine Rutan, CPHQ
National Director
Real World Evidence and Health Information Technology
American Heart Association

Mark McClellan, M.D., Ph.D
Director & Robert J. Margolis M.D. Professor of Business, Medicine and Policy
Margolis Center for Health Policy
Duke University

Kathleen Gondek, PhD
Global Head of Evidence and Outcomes
Takeda

Ryan D. Kilpatrick, PhD
Head of Global Epidemiology
Pharmacovigilance & Patient Safety
AbbVie

Rhys Williams
Vice President 
Global Health Economics and Outcomes Research (HEOR)
Sunovion

Rebecca Meisberger
Director
Real World Evidence
Global Patient Outcomes & Real World Evidence
Eli Lilly and Company